KRYS (Krystal Biotech) Cyclically Adjusted FCF per Share: $-0.88 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KRYS Krystal Biotech Inc KRYS
55 GF Score
Price $332.86
GF Value $329.79
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Krystal Biotech Cyclically Adjusted FCF per Share?

Krystal Biotech KRYS +1.78% 55 Cyclically Adjusted FCF per Share is $-0.88 as of Jun. 2026. GuruFocus rates KRYS with a GF Score™ of 55/100 and a GF Value™ of $329.79 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Krystal Biotech's adjusted free cash flow per share for the three months ended in Jun. 2026 was $2.323. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.88 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-12), Krystal Biotech's current stock price is $332.86. Krystal Biotech's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was $-0.88. Krystal Biotech's Cyclically Adjusted Price-to-FCF of today is .


Krystal Biotech  (NAS:KRYS) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Krystal Biotech Cyclically Adjusted FCF per Share Related Terms


Krystal Biotech Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Krystal Biotech's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Krystal Biotech Cyclically Adjusted FCF per Share Chart

Krystal Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Krystal Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.88

KRYS vs NUVL, HALO, APGE: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Krystal Biotech's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Krystal Biotech Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's Cyclically Adjusted Price-to-FCF falls into.


KRYS
55GF Score
Krystal Biotech Inc KRYS
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Krystal Biotech Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Krystal Biotech's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.323/333.9520*333.9520
=2.323

Current CPI (Jun. 2026) = 333.9520.

Krystal Biotech Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.073 241.428 -0.101
201612 -0.204 241.432 -0.282
201703 -0.062 243.801 -0.085
201706 -0.051 244.955 -0.070
201709 -0.265 246.819 -0.359
201712 -0.222 246.524 -0.301
201803 -0.230 249.554 -0.308
201806 -0.157 251.989 -0.208
201809 -0.183 252.439 -0.242
201812 -0.259 251.233 -0.344
201903 -0.341 254.202 -0.448
201906 -0.375 256.143 -0.489
201909 -0.315 256.759 -0.410
201912 -0.535 256.974 -0.695
202003 -0.446 258.115 -0.577
202006 -0.381 257.797 -0.494
202009 -0.557 260.280 -0.715
202012 -0.773 260.474 -0.991
202103 -0.571 264.877 -0.720
202106 -0.636 271.696 -0.782
202109 -1.272 274.310 -1.549
202112 -2.674 278.802 -3.203
202203 -1.301 287.504 -1.511
202206 -2.332 296.311 -2.628
202209 -1.317 296.808 -1.482
202212 -1.072 296.797 -1.206
202303 -1.227 301.836 -1.358
202306 -1.387 305.109 -1.518
202309 -0.796 307.789 -0.864
202312 -0.315 306.746 -0.343
202403 0.499 312.332 0.534
202406 -0.179 314.175 -0.190
202409 1.933 315.301 2.047
202412 1.737 315.605 1.838
202503 0.829 319.799 0.866
202506 1.708 322.561 1.768
202509 1.272 324.800 1.308
202512 2.486 324.054 2.562
202603 2.401 330.213 2.428
202606 2.323 333.952 2.323

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.88 mean?
Krystal Biotech (KRYS) has a Cyclically Adjusted FCF per Share of $-0.88 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Krystal Biotech and its competitors.
Is Krystal Biotech's Cyclically Adjusted FCF per Share too high?
Krystal Biotech's current Cyclically Adjusted FCF per Share is $-0.88. Overall, Krystal Biotech has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Cyclically Adjusted FCF per Share compare to NUVL and HALO?
Krystal Biotech's Cyclically Adjusted FCF per Share of $-0.88 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Krystal Biotech and its competitors. Krystal Biotech's current Cyclically Adjusted FCF per Share is $-0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (KRYS) is currently considered Fairly Valued. The stock's GF Value™ is $329.79, compared to a current price of $332.86 — trading 0.9% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-0.88. Krystal Biotech's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Krystal Biotech (KRYS), the current Cyclically Adjusted FCF per Share is $-0.88 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krystal Biotech (KRYS) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of $332.86 is trading 0.9% above its estimated GF Value™ of $329.79. GuruFocus considers Krystal Biotech to be Fairly Valued.

Key valuation signals for KRYS:

  • Cyclically Adjusted FCF per Share: $-0.88
  • GF Value™: $329.79 vs. price of $332.86 (0.9% above fair value)
  • GF Score™: 55/100 with 2 warning signs

No single metric tells the full story. See the KRYS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Krystal Biotech Business Description

Other Exchanges 1KRYS:Italy4KB:Germany
Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
55GF Score

Get the complete analysis for KRYS

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$332.86
Price
$329.79
GF Value